The Role of Breast Cancer Derived Prostaglandin E2 in the Elaboration of a Therapeutic Immune Response

Abstract

The principal goal was to understand why breast cancer cells are able to evade the host immune system despite the presence of tumor antigens and tumor antigen-specific T lymphocytes. We had previously demonstrated that tumor-derived prostaglandin E2 (PGE2) directly contributes to the lack of a significant immune response to breast cancer cells. However, the production of PGE2 by breast cancer cells did not completely explain the immune suppressive effect of breast cancer cells. We have subsequently demonstrated that GA733-2/mEGP, a type I cell surface breast cancer protein, is able to efficiently block the presentation of a variety of antigens from dendritic cells (DC) . Murine DC expressing mEGP were unable to stimulate allogeneic T cell responses or responses to model tumor antigens.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2000
Accession Number
ADA388513

Entities

People

  • Stephen Eck

Organizations

  • University of Pennsylvania

Tags

DTIC Thesaurus Topics

  • Breast Cancer
  • Cells
  • Chemical Synthesis
  • Chemistry
  • Epithelial Cells
  • Gene Therapy
  • Health Services
  • Immune System
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Therapy

Fields of Study

  • Biology
  • Medicine

Readers

  • Immunology and Pathology
  • Oncology (Cancer Research).